Communiqués GSK plc

Actions

GSK

GB00BN7SWP63

Produits pharmaceutiques

Temps réel estimé Cboe Europe 15:51:18 25/09/2026			Varia. 5j.	Varia. 1 janv.
1 857,25 ^GBX	-1,05 %		-0,80 %	+2,08 %

07:51	Le Nasdaq tient tête à l'obligataire
03:25	Singapour accélère la production locale de vaccins antigrippaux à ARN messager pour renforcer sa préparation aux pandémies	MT

Communiqués

17/09	ViiV Healthcare Partners with Prevention Access Campaign (PAC) to Celebrate 10 Years of U=U and Look to The Future	BU
15/09	Empowering Communities: ViiV Healthcare Awards $33 Million in Grants to Advance HIV Response in the U.S.	BU
15/09	GSK : to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences	PU
14/09	GSK : presents positive registrational data to potentially expand Jideytro (zidesamtinib) to first-line ROS1-positive non-small cell lung cancer	PU
13/09	GSK : Ris-Rez reduced risk of death by 54% versus topotecan in patients with relapsed small cell lung cancer in China	PU
24/08	GSK : Hibsago (bepirovirsen) approved in Japan as first and only functional cure for chronic hepatitis B	PU
24/08	GSK : Jemperli (dostarlimab) accepted for priority review by the US FDA for dMMR/MSI-H locally advanced rectal cancer	PU
04/08	ViiV Healthcare Launches “Do It For Future You” Campaign Inspiring People to Prioritize Their Sexual Health and Future	BU
28/07	Glaxo: Q2 Earnings Snapshot	AQ
28/07	GSK : Q2 2026 US dollar translation	PU
28/07	GSK : delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026	PU
23/07	GSK plc - Jideytro approved in the US for previously treated ROS1-positive non-small cell lung cancer	AQ
22/07	GSK : Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer	PU
20/07	GSK : European Medicines Agency accepts submission to update Bexsero label for 1-dose Meningitis B booster in 10+ year olds	PU
17/07	GSK : provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (RCC)	PU
15/07	What If A Shingles Jab Could Also Protect Your Brain?	AQ
15/07	GSK : completes acquisition of Nuvalent, Inc.	PU
13/07	GSK : Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer	PU
10/07	GSK : licensor Hansoh Pharma announces positive phase III results for Ris-Rez in China patient population	PU
09/07	GSK : Roy Jakobs to join GSK Board as Non-Executive Director	PU
24/06	GSK : announces commencement of tender offer to acquire Nuvalent, Inc.	PU
17/06	Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)	BU
17/06	GSK : Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)	PU
01/06	PrEP Wisdom: ViiV Healthcare Launches New Campaign to Support Informed HIV Prevention Choices	BU
28/05	GSK : Bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B	PU